Virtual Library

Start Your Search

Ryo Takahashi



Author of

  • +

    P2.06 - Mesothelioma (ID 170)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Mesothelioma
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.06-08 - Nivolumab for Malignant Mesothelioma: A Real-World Experience (ID 1484)

      10:15 - 18:15  |  Author(s): Ryo Takahashi

      • Abstract
      • Slides

      Background

      Nivolumab, an anti-PD-1 monoclonal antibody, has beneficial effects against pretreated malignant pleural mesothelioma (MPM). Although this drug is approved in Japan, data on the efficacy and safety of nivolumab in MPM are limited to those from a small number of patients of the MERIT study. Therefore, it is important to accumulate real-world data of nivolumab.

      Method

      We retrospectively analyzed all patients with MPM who received nivolumab at Hyogo College of Medicine Hospital from August 2018 to December 2018. The tumor response was assessed according to RECIST guidelines (version 1.1), and adverse events were evaluated according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

      Result

      A total of 39 patients (31 males and 8 females)were included. There were 29, 6, and 4 patients with a performance status of 0-1, 2, and 3, respectively. There were 34, 4, and 1 patientswith epithelioid, sarcomatoid, and bi-phasic histology, respectively. Nivolumab was given as second-, third-, and ≥fourth-line treatment to 18, 10, and 11 patients, respectively.

      The response rate (RR)was 20.5% (8/39), and disease control rate (DCR)was 56.4% (22/39). Twelve patients were evaluated asprogressive disease and 5 patientswere not evaluable. The RR and DCR were 11.8% (4/34) and 50.0% (17/34) in the epithelioid-type, and 50.0% (2/4) and 100.0% (4/4)in the sarcomatoid-type.The median progression-free survival was 4.1 months and median overall survival was not reached. Regarding adverse events, fatigue (grade 1−2) was observed in 8, hypothyroidism (grade 1-2) in 4, renal dysfunction (grade 1-2) in 3, loss of appetite (grade 1-2) in 2, pneumonitis (grade 3) in 1, rash (grade 1) in 1and hypopituitarism (grade 2) in 1 patients, respectively.

      Conclusion

      The findings of this retrospective study revealed the effectiveness and safety of nivolumab for MPM in the real-world setting. Nivolumab can be used as a standard second-line treatment for MPM.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.